51 results about "Ipratropium bromide" patented technology

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.< / PTEXT>

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The invention provides a synthesis method of ipratropium bromide. The method comprises the steps of (1) carrying out acetyl protection reaction on tropic acid as a raw material to obtain a compound 1; (2) carrying out chloroformylation reaction on the compound 1 to obtain a compound 2; (3) dissolving isopropyl tropine and organic acid into dichloromethane, adding obtained solution to the compound 2 and carrying out acylation reaction to obtain a compound 3; (4) carrying out alcoholysis reaction on the compound 3 to obtain a compound 4; and (5) carrying out bromine methylation reaction on the compound 4 to obtain the ipratropium bromide. The synthesis method of the ipratropium bromide is simple and raw materials are easily available, the operation is simple and stable, various steps are mild in reaction conditions, reaction products of various steps are easy to purify, the purity of the obtained ipratropium bromide product reaches over 97% and the synthesis method is suitable for industrial production of ipratropium bromide.

The invention discloses a preparation method of ipratropium bromide. The method comprises the following steps that as a starting material, methyl phenylacetate (III) undergoes the substitution reaction to produce alpha-formyl methyl phenylacetate (IV); tropic alcohol reacts with bromomethane to produce a compound (II); the compound (II) reacts with a compound (IV) to produce a compound (V); the compound (V) undergoes a reductive reaction to produce ipratropium bromide anhydrous substance, and then ipratropium bromide (VII) is produced through refining preparation. The method has the advantages of simple operation, high safety, a low cost and suitability for industrial production.

The invention discloses an electroplating solution with excellent performance. The electroplating solution consists of the following raw material components: 20-25 parts of antimony trioxide, 150-200 parts of ferrous sulfate, 100-120 parts of copper sulfate, 130-150 parts of nickel sulfate, 100-120 parts of stannous chloride, 30-50 parts of aluminum sulfate, 30-40 parts of zinc carbonate, 8-10 parts of ammonium citrate, 6-8 parts of dipotassium hydrogen phosphate, 8-10 parts of potassium tartrate, 5-8 parts of potassium citrate, 8-10 parts of cocamidopropyl betaine, 6-8 parts of sodium lauryl sulfate, 3-5 parts of ipratropium bromide and 100-150 parts of deionized water. The electroplating solution with the excellent performance is strong in corrosion resistance, can reduce pollution, is an ideal plated layer, and can maintain the metal concentration of the plated layer used by the electroplating solution, and an obtained plated layer is high in brightness, strong in corrosion resistance, and capable of meeting use requirements of severe environments.

The invention discloses a method for detecting formic acid, acetic acid and acetone in an ipratropium bromide solution for inhalation, and solves the problem that a method for simultaneously determining formic acid, acetic acid and acetone in the ipratropium bromide solution for inhalation is unavailable in the prior art. According to the detection method disclosed by the invention, reversed-phasehigh-performance liquid chromatography is adopted for detection, diisopropyl substituted octadecylsilane bonded silica is used as a filler, a buffer salt solution with the pH value of 2.0-3.3 is usedas a mobile phase A, and an organic solvent is used as a mobile phase B, formic acid and acetic acid are eluted according to a ratio of A to B being (90-100):(0-10) to generate peaks, and then acetone is eluted according to a ratio of A to B being (75-100):(0-25) to generate peaks; the organic solvent is selected from one or more than two of acetonitrile, isopropanol, ethanol, tetrahydrofuran andmethanol. According to the method, the formic acid, the acetic acid and the acetone in the ipratropium bromide solution for inhalation can be rapidly and accurately measured, the product quality of the ipratropium bromide solution for inhalation is effectively guaranteed, and the medication safety is guaranteed.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.

The invention relates to a drug ipratropium bromide spray for treating respiratory diseases, especially asthma, chronic obstructive pneumonia, trachitis and the like. An inhalable surfactant can makethe spray particle size, the spray time and the spray speed of the composition more suitable by adjusting the surface tension of the ipratropium bromide spray pharmaceutical composition without a propellant.

The invention discloses a compound doxofylline solution for inhalation and a preparation method thereof. The compound doxofylline solution for inhalation comprises the following components: an active pharmaceutical ingredient, an isoosmotic adjusting agent, an antioxidant, a pH regulator and water for injection, and the active pharmaceutical ingredient comprises a mixture of doxofylline and ipratropium bromide. The compound doxofylline solution for inhalation disclosed by the invention is suitable for patients needing combined application of multiple bronchodilators, is used for treating reversible bronchospasm related to airway obstructive diseases, and has more stable quality and is safer and more convenient to use in comparison with the prior art.

The invention relates to a preparation method of a compound ipratropium bromide solution for inhalation, which comprises the following steps: S1, adding injection water accounting for 75% of the total preparation amount into a liquid preparation tank, and cooling the injection water to below 40 DEG C; s2, taking injection water accounting for 5% of the total preparation amount, cooling to 50-70 DEG C, adding sodium chloride, stirring, pouring into a liquid preparation tank, uniformly stirring, and adding diluted hydrochloric acid to obtain a first acidic solution; s3, taking injection water which accounts for 1-3% of the total preparation amount and is cooled to room temperature, adding ipratropium bromide, stirring, pouring into a liquid preparation tank, and uniformly stirring; s4, taking the injection water which accounts for 7-15% of the total preparation amount and is cooled to room temperature, adding diluted hydrochloric acid to obtain a second acidic solution, adding salbutamol sulfate while stirring, stirring and dissolving until the solution is clear, and pouring the solution into a liquid preparation tank for stirring; and S5, adding the remaining water for injection according to the prescription amount to the total preparation amount, stirring until the solution is uniformly stirred, adjusting the pH value of the solution to 3.0-3.5, and uniformly stirring.

The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide in a 0.5 ml volume.

The invention belongs to the technical field of textile auxiliaries and discloses a propofol phosphate gas defoamer. The propofol phosphate gas defoamer is prepared from the following components in parts by weight: 0.1 to 0.8 part of propofol phosphate, 0.5 to 1.7 parts of ipratropium bromide, 100 to 150 parts of nitrogen, 15 to 20 parts of helium, 1 to 4 parts of oxygen, 0.1 to 1.5 parts of carbonic oxide, 12 to 14 parts of argon and 10 to 15 parts of ethanol. The preparation method of the propofol phosphate gas defoamer comprises the following steps: dissolving propofol phosphate into an ethanol solution, heating and stirring at the temperature of 30 to 40 DEG, collecting evaporation gas and mixing the evaporation gas with nitrogen; then mixing the mixed gas with isopropyl ammonium bromide aerosol, subsequently carrying out ultraviolet irradiation treatment for 1 to 2 hours, and mixing a treated mixture with other gases, thus obtaining a finished product. The gas defoamer is introduced into the bottom of a working bath for use, wherein the use amount of working solution per liter is 1 to 2L per minute; by means of adding gas, the dispersion uniformity of the working bath is improved; at the same time, a good foam eliminating and inhibiting effect is achieved; the propofol phosphate gas defoamer can be recycled and is high in economic benefit.

The present invention relates to a novel process for the preparation of anticholinergic agents / drugs, such as umeclidinium bromide, tiotropium bromide, glycopyrronium bromide, aclidinium bromide, ipratropium bromide (V), in a continuous flow mode in the presence of one or more polar protic solvents. The anticholinergic agents are useful in the treatment of respiratory diseases, such as asthma or chronic obstructive pulmonary disease (COPD), in a form suitable for inhalation.

The invention provides a preparation method of a choline receptor antagonist. The choline receptor antagonist is ipratropium bromide. According to the method provided by the invention, alpha-formyl phenylacetic acid is taken as an initial raw material and reacts with isopropyl tropine alcohol to generate a compound II, the compound II is subjected to a reduction reaction to generate a compound III, and the compound III reacts with bromomethane to generate ipratropium bromide. Compared with the prior art, the method is easy to operate, high in safety, low in cost, high in yield and product purity and more suitable for industrial production.

The invention discloses a compound doxofylline solution for inhalation and a preparation method thereof. The components of the compound doxofylline solution for inhalation include crude drug, isotonicity regulator, antioxidant, pH regulator and water for injection , the crude drug comprises a mixture of doxofylline and ipratropium bromide. The compound doxofylline solution for inhalation of the present invention is suitable for patients who need the combined application of multiple bronchodilators, and is used for the treatment of reversible bronchospasm related to airway obstructive diseases. Compared with the prior art, the quality is more stable , Medication is safer and more convenient.